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Anti-peptide x1 (l-9) and anti-peptide cl, (459-467) antibodies coupled to Affigel- IO were used for the isolation of GABAA receptors containing 
the q- or q-subunit, respectively. Both types of GABA& receptors exhibited a high affinity for [3H]Runitrazepam. and binding of PHlAunitrazepam 
was stimulated in the presence of GABA. GABAA receptors eluted from the anti-peptide I, (l-9) immunoaffinity column exhibited a high affinity 
and those from the anti-peptide q (459467) columns a low affinity for the type I benzodiazepine receptor-selective ligand Cl 218872, indicating 
the enrichment of type I and type II GABAA-benzodiazepine receptors, respectively. 
GABAA-benzodiazepine receptor; Immunoaffinity chromatography: Type I and type II GABA* receptor; Flunitraxepam binding: Radioautography 
1. INTRODUCTION 
The GAE3AA receptor of mammalian brain is a 
ligand-gated chloride ion channel and the site of action 
of several important classes of drugs like benzodia- 
zepines, barbiturates, convulsant compounds and some 
steroids [ 11. This receptor has been purified to apparent 
homogeneity by benzodiazepine-affinity chromato- 
graphy and seems to consist of several different protein 
subunits [2]. Molecular cloning studies not only have 
identified their amino acid sequence but also have de- 
monstrated the existence of a significant heterogeneity 
of individual subunits. Thus, so far the existence of 6 cy- 
4,8-, 2 y- and 1 d-subunit of the GABAA receptor has 
been demonstrated [3]. Studies on the expression in 
Xenopzts oocyres and mammalian cells of the various 
subunits revealed that GABA-gated chloride ion chan- 
nels modulated by benzodiazepines and ,8-carbolines 
can only be produced by the simultaneous presence of 
CY-, fi- and y-subunit cDNAs in the cells [4]. This seems 
to indicate that at least three different subunits are 
necessary to reconstitute GABAA-benzodiazepine 
receptors with correct pharmacology. In addition, it has 
been demonstrated that depending on the type of cy- 
subunit cDNA used for the co-expression withp- and y- 
subunit cDNAs, GABA,\-benzodiazepine receptors 
with different GABA and bcnzodiazepinc binding pro- 
perties are produced [S,6]. 
Recently, polyclonal antibodies directed against parts 
of the amino acid sequence of the CYI-, cw and a(.~- 
subunits were raised [7-g]. These antibodies, each of 
which selectively recognized a single protein in purified 
GABA. receptor preparations not only were used for 
the identification of the corresponding a-subunits [7,8] 
but also for the separation of GABAA-benzodiazepine 
receptors containing the respective a-subunits by im- 
munoaffinity chromatography (Zezula et al., submit- 
ted). In this study, however, receptors were eluted from 
the affinity columns by a change of pH. This resulted in 
the inactivation of the eluted GABA,, receptors. In the 
present study a different method was used for the elu- 
tion of the receptors from the affinity columns. Recep- 
tors eluted by this method were still able to bind GABA 
or benzodiazepines. The properties of receptors eluted 
from different immunoaffinity columns were com- 
pared. 
2. MATERIALS AND METHODS 
Anti-pepride nl( l-9), anli-pcptide ~~(416-424) and anti-peptidc 
a2(459-467) antibodies were isolated by affinity chroma~ograph) 
front sera of rabbits immunized whh 1hc respec1ivc pep1idcs coupled 
10 keyhole-limper hacmocyonin [S]. Purified antibodies sclcctivcly 
recognized their respective peptidc and GABA., receptors purified 
from the brains of 5-IO-day-old rats as measured by ELISA. im- 
niunoprccipiration and Ws1crn blor techniques [8]. 
Irnnwnoaffini~y columns wrc prcpnrcd by coupling of IO mg 
purified anti-pcp1idc anribodics IO 5 ml of wet Affigcl IO using stand- 
ard nwhods (UIO-HAD). The 10~1 binding capacity of these colun~ns 
\vas about 30-W pmol [“tl]fluniirazcpaii~ binding si1cs tvhcn rhc col- 
umns wcrc freshly synthcsizcd. Howwr, since lhc columns had IO bc 
wshcd wi1ll a buffer coulnininy 0,24’0 frilon X-100 and 0.1 hl 
glycinc-HCI, pH 2.4 nftcr carh run in order to complc~cly rcniovc 
C’,AlM.\ rcccplors bound lo 1hc colun~ns. and since ~hc rabbi1 anti- 
bodies irrcvcrsibly bound lo the columrls lcakctl front IIW colunlns al 
acid pH, I~C binding capa&:* declined will1 lime. 
GADA, rcceplors wcrc csiraclcd from brain nlcnlbrilncs of 
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5-lo-day-old rats by constant agitation for 2 hat 4°C in a buffer con- 
taining 2% Triton X-100, 0.3 M KCI. 10 mM HEPES, pH 7.4, 
0.5 mM dithiothreitol, I mM EDTA. I mM benzamidine, 0.1 mg/ml 
bacitracine and 0.3 mM phenylmethylsulfonylfluoride (PMSF). The 
suspension was centrifuged for 30 min at 200000 x g, and the supcr- 
natant was then applied to the immunoaffinity columns. 
3. RESULTS AND DISCUSSION 
GABAA-benzodiazepice receptors present in extracts 
from the brain membranes of 5-lo-day-old rats were 
subjected to SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western blot analysis. As shown in 
Fig. 1, a mixture of anti-peptide al(l-9), anti-peptide 
~~~(416-424) and anti-peptide cu3(459-467) antibodies 
was able to recognize at least three proteins with ap- 
parent molecular weight 51000 (PSI), 53000 (Ps~) or 
59000 (Pss). The same proteins have been identified 
previously in GABAA-benzodiazepine receptor prepara- 
tions purified from the brains of 5-lo-day-old rats and 
have been demonstrated to be the NI-, LYZ- and as-sub- 
units of the GABA++, receptors, respectively [8]. 
30-40 ml of the brain membrane extracts correspon- 
ding to a total of about 125 pmol reversible [31-!]fluni- 
trazepam binding sites were applied to anti-peptide 
cu,(l-9), anti-peptide n2(416-424) or anti-peptide 
@3(459-467) immunoaffinity columns at a rate of 
20 ml/h. 15-40% of the applied GABAA receptors 
were retained by the columns, depending on the type of 
antibody bound to the coiumn and on the age of the col- 
umns as mentioned in section 2. The columns were 
washed with 15 times of their volume using the extrac- 
tion buffer complemented with additional KC1 to result 
in a total of 0.6 M KC1 in order to remove unspecifical- 
ly bound proteins and were subsequently equilibrated 
with 5 volumes of a low salt, low Triton X-100 buffer 
containing 10 mM HEPES, pH 7.4, 150 mM KCI, 
0.2% Triton X-100, 1 mM EDTA, 0.5 mM dithio- 
threitol, 1 mM benzamidine and 0.3 mM PMSF. 
In order to find conditions which result in the elution 
of GABAA receptors still able to bind benzodiazepines, 
several different chaotropic agents were investigated as 
eluents. It was found that a 0.2% Triton X-100 solu- 
tion, pH 7.4, containing either 3 or 5 M MgCl2, or 3 M 
urea plus 3 M MgCl2, 3 M urea plus 5 M M&12, 3 M 
urea alone, 3 M urea plus 5 M NaJ, 5 M NaJ alone, or 
1 M NaSCN plus 1 M KC1 were able to elutc GABA,,- 
benzodiazepine receptors as demonstrated by a [‘HI- 
flunitrazcpam binding assay in column eluates dialyzed 
overnight against 1000 vols of a buffer containing 
10 mM HEPES, pH 7.4, I50 mM KCI, O.tolo Triton 
X-100, I mM EDTA, 0.5 mM dithiothreitol and 1 mM 
benzamidinc, The relatively largest atnount of GABA,,- 
benzodiazepine receptors was clutcd by a 0.2plo Triton 
X-100 solution containing 3 M urea plus 3 M M&II. 
S-20’% r>f the GABA,, receptor rctaincd by the anti- 
peptidc n1(1-9) and anti-pcptide (vJ(459-467) coiun~n 
could bc cluted under these conditions in LI form still 
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Fig. 1. Comparison of a-subunit proteins present in brain membrane 
extracts and eluates from two different immunoaffinity columns. 
Proteins in brain membrane extracts or in immunoaffinity column 
eluates were subjected to SDS-PAGE, transferred to nitrocellulose 
and probed with a mixture of anti-peptidc cu,(l-9), anti-peptide 
~~(416-424) or anti-pcptide a>(459-467) antibodies, an anti-rabbit 
IgG F(ab’)z antibody conjugated to alkaline phosphatase (Jackson 
lmmuno Research Labs, USA) and the alkaline phosphatase 
conjugate substrate kit (BIO-RAD). The experiment was performed 3 
times with similar results. 
able to bind [‘Hlflunitrazepam. The elution of GABA*- 
benzodiazepine receptors was therefore routinely per- 
formed with a 0.2% Triton X-100 solution, pH 7.4, 
containing 3 M urea and 3 M MgClz in all subsequent 
experiments. 
Interestingly, although GABAA receptors were re- 
tained by the antipeptide ~~(416-424) immunoaffinity 
column, in contrast to the anti-peptide al(I-9) or anti- 
peptide cu3(459-467) immunoaffinity columns a rather 
low amount of protein was cluted from this column us- 
ing 0.2% Triton X-100, 3 M urea and 3 M MgCl2. 
GABA,, receptor proteins, however, were eluted from 
this column using a buffer containing 0.2% Triton 
X-100 and 0.1 M glycine-HCI, pH 2.4. In agreement 
with previous results (Zezula et al., submitted), GABA,, 
receptors cluted by such a change of the pH no longer 
were able to bind [‘Hlflunitrazcpam even when the col- 
umn eluatc was immediately neutralized by addition of 
3 M Tris-Cl buffer, pH 7.4. Thus, the elution tncthod 
using a 0.2% Triton X-lOOsolution containing ur:a and 
magnesium chloride could not be used to isolate suffi- 
cient amounts of GABAn receptors from columns con- 
taininp the anti-peptidc n2(41G-424) antibody. 
Thcrcforc all furrher experiments w’crc pcrformcd with 
eluater from the anti-pcptidc til(l-9) or the anti- 
pcptick (.r.1(459-467) colutnt~ only. 
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GABAA receptors eluted from the anti-p~ptide 
mr(l-9) or anti-peptide ~~~(459-467) columns using a 
solution containing 0.2% Triton X-100, pH 7.4, 3 M 
urea and 3 M MgCl2 were subjected to SDS-PAGE and 
Western bIot analysis. For the detection of the respec- 
tive subunits a mixture of anti-peptide at(I-9), anti- 
peptide at(416-424) and anti-peptide cy3(459-467) an- 
tibodies was used. As shown in Fig. 1 in the GABAA 
receptor fractions eluted from anti-peptide cyr( 1-9) or 
anti-peptide a3(459-467) columns, the cur(Protein PSI)- 
or cv3(Protein P&subunits of the GABAh receptors 
were strongly enriched. These results support a previous 
report [9] indicating that most, if not al1 GABAA recep- 
tors contain only a single type of a-subunit. 
In addition to the ‘YI- or acr-subunits predominantly 
retained by and eluted from the respective immunoaf- 
finity columns other proteins were present in the col- 
umn eluates in small amounts and were weakly labeled 
by the mixture of anti-peptide CYI, anti-peptide cyz and 
anti-peptide ~3 antibodies (Fig. 1). Thus, these weakly 
labeled proteins are CYI-, CQ- or ~3-subunits of the 
GABAA receptor not completely removed from the cy- 
subunits specifically retained by the immunoaffinity 
column. Since these contaminating a-subunits were 
detected in the column eluate even after extensive 
washing of the immunoaffinity columns, their presence 
in the column eluate might be due either to aggregated 
GABA,, receptors containing other a-subunits or to a 
colocalization in a rather minor part of the receptors of 
two or more different a-subunits in the same GABAA 
receptor complex. A minor contribution of such recep- 
tors cannot be excluded by the data so far available [9]. 
In order to investigate the possible presence of ,.Q- and 
y-subunits of the GABAA receptors in eluates from 
anti-peptide ar(l-9) or anti-peptid~ lu3(459-467) im- 
munoaffinity columns, these eluates were probed in im- 
munoblots using the&subunit-specific monoclonal an- 
tibody bd- 17 [lo] or a yr-subunit-specific polyclonal an- 
tibody provided by I-I. Mohler [ 111. The same antibody 
specific protein staining pattern was observed in im- 
munoblots from brain membrane extracts as from anti- 
peptide a1(1-9) or anti-peptide &459-467) column 
eluates (experiments not shown). These data indicate 
the presence of fl- and yz-subunits in the immunoaffini- 
ty column eluates. 
In order to compare the binding properties of 
GABA,~-benzodiazepine receptors before or after im- 
munoaffinity chromatography, Scatchard analysis of 
[3H]flunit:azepam binding (concentration range 0.5-10 
nM) in the absence or presence of 2 FM diazepam was 
performed in membrane extracts and dialyzed immuno- 
affinity column eluates. As shown in Table I, GABAA 
receptors in membrane extracts or eluates from anti- 
peptide crt(l-9) or anti-peptide u&459-467) columns 
exhibited a similar high affinity for ~3~]~unitrazepam. 
In addition, GABA was able to stimulate binding of 
[‘Hlflunitrazepam to receptors from anti-peptide 
crr(l-9) or anti-peptide cu3(459-467) column eluates. 
GABA stimulation of r3H J~unitrazepam binding to 
membrane extracts was not determined due to the 
presence of endogenous GABA in those extracts. In 
order to investigate a possible differential affinity of 
GABAA receptors eluted from the different immunoaf- 
finity columns, the potency of the type I benzodiazepine 
receptor-selective ligand Cl 218872 for displacement of 
[3H]fIunitrazepam binding was investigated in dialyzed 
eluates from anti-peptide cur(l-9) and anti-peptide 
a3(459-467) columns. In contrast to membrane ex- 
Table I 
Properties of GABA,, receptors present in membrane extracts or in cluates from the 
imtnunoaffinity columns 
lOOpI membrane extracts or dialyzed cluatcs from the immunoaffinity columns were 
incubated for 90 min at 4°C either with 2.5 nM or with various concentrations (0.5-10 nM) 
of [“H]flunitrazepam in the absence or presence of 2 /tM diazepam, 100 PM GABA or various 
concentrations of Cl 218872 in I ml of a solution containing 50 mM Tris-citrate, pH 7.4, 
150 mM NaCI, 50,~rg r-globulin and a total of lSa/o of polpethyleneglycol. Samples \vcre 
filtered through Whatman GFK filters and washed 3 titnes with a solution containing 50 mM 
Tris-citrate, pH 7.4 and 8D70 pol~ettyyiene~l~col and radioactivity on ihe filter was measured. 
Nonspecific binding (estimated in the presence of 2 PM diazcpam) was sttbtractcd from total 
binding IO yield specific binding. Equilibrium binding data of [‘H]flunitrazepam \vcrc 
subjected to Scatchard analysis (linear rcprcssion). ICya values were dctcrmincd by linear Icast- 
squares fit of the data to the Hill~equat~o~l, Hesutts arc means + SE with number of 
e~peritncllts pcrforl~~cd in duplicates in ~)aret~tltcses, n.d. = not detcrntittcd. 
Mcmbrnnc Anti-txplidc w Anti-pcptidc TYJ 
cstract COlUllt~! ClIIitIe COlLIltlu CllIifI~! 
[~H]~lun~tr~zel~aIl~ 
binding, h’,t (1tF1) 2.3 f a.2 (5) 2.8 k 0.2 (3) 2.4 ZtZ (I.2 (4) 
2,s IIXI [‘I~)~~luIiitrazcpanr f 
100 /<Xl GABA 
(% of coIllrolf tt,d. I38 ” 6 (3) 139 A s (3) 
iC’r,, <IPA) Cl 218872 IiS * 26 (J) 317 % .tn (4) 140~ k I40 (4) 
_ 
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tracts, in which the potency of Cl 218872 was inter- 
mediate, the potency of Cl 218872 for inhibition of 
[3H]flunitrazepam binding to eiuates from the anti- 
peptidecr,(i-9) column was higher than that for eluates 
from the anti-peptide aJ(459-467) column. These data 
are consistent with the enrichment of type I and type II 
GABAA-benzodiazepine receptors by the anti-peptide 
(YI( 1 -Q)- and anti-peptide a3(459-467) immunoaffinity 
columns, respectively. 
Thus, in the present investigation for the first time 
type I and type II GABAA-benzodiazepine receptor sub- 
types with retained binding properties were enriched 
and separated from other possible GABAA-benzodia- 
zepine receptor subtypes. The binding properties of the 
isolated type I and type II receptors were similar to but 
not identical with those of artificial receptors arising by 
the co-expression of a~-, ,&I- and yz- or (YJ-, PI- and 
y2-subunits in embryonic kidney cells [6]. One reason 
for this discrepancy might be the possibility that the ar- 
tificially expressed receptors either by their subunit 
composition, their state of giycosylation or their lipid 
environment might not be identical with receptors ex- 
pressed in vivo and isolated by immunochromato- 
graphy. Other reasons could be the contamination of 
the cYI-subunit containing type I or the cys-subunit con- 
taining type II receptors by small amounts of receptors 
containing different a-subunits as indicated by Fig. 1. 
And finally, the anti-peptide cr1(1-9) or anti-peptide 
a3(459-567) columns presumably will not distinguish 
between GABAA-benzodiazepine receptors containing 
different,& or y-subunits but the same a-subunit. Thus, 
if such receptors existed in vivo, various GABAA recep- 
tors containing combinations of different ,& or y-sub- 
units but the same a-subunit will be coenriched by the 
anti-peptide CYI or anti-peptide a3 columns and add to 
the overall binding properties measured in the separated 
receptors. Further experiments using antibodies highly 
specific for the various& and y-subunits (which are not 
available yet), will have to be performed to investigate 
the possible existence of different @- or y-subunits in 
immunoaffinity purified GABAA receptors containing 
a single c+subunit. 
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